TIPS-11 EFFICACY AND SAFETY OF STUPP REGIMEN WITH OR WITHOUT ANLOTINIB FOR NEWLY DIAGNOSED GLIOBLASTOMA: INTERIM RESULTS OF A MULTICENTER, DOUBLEBLIND, RANDOMIZED PHASE II TRIAL
Y. Chen,G. Liu,P. Sun,M. Li,X. Yang,L. Pan,L. Wang,Y. Hua,M. Zhao,Y. Liu,J. Ran,H. Cai,X. Lu,H. Jiang,X. Li,W. Zheng,Z. Liu,S. Lin,M. Deng,Q. Yang,C. Guo,J. Li,Z. Chen
DOI: https://doi.org/10.1093/neuonc/noae144.469
2024-01-01
Neuro-Oncology
Abstract:Abstract BACKGROUND The STUPP regimen, which consists of postoperative radiotherapy with concurrent temozolomide (TMZ) followed by up to six cycles of adjuvant TMZ chemotherapy, is the established standard treatment for newly diagnosed glioblastoma (GBM). However, its effectiveness is limited. Anlotinib, a multi-kinase inhibitor targeting tumor angiogenesis and cell proliferation, has demonstrated promising results in preclinical GBM models and phase I clinical trials. In order to assess the efficacy and safety of combining the STUPP regimen with anlotinib, we conducted a phase II trial aimed at evaluating their combined effects. (NCT 04959500). MATERIAL AND METHODS This study is a multicenter, double-blind, randomized, placebo-controlled trial with an expected 150 patients randomly assigned 1:1 ratio to receive TMZ-based radiochemotherapy with anlotinib or placebo. Eligibility criteria include histologically confirmed GBM, ECOG performance score ≤2, age ≥18 years, and lack of significant comorbidity. The primary endpoint is median progression-free survival (PFS), while secondary endpoints include 1-year overall survival rate, PFS at 6 months, overall response rate, duration of response, disease control rate, quality of life, and toxicity. RESULTS From July 2021 to April 28th, 2024, 153 patients were enrolled. The results in this abstract were all obtained without exposing the blind state. The median PFS was 10.22 months (95% CI, 9.43-11.93) in the overall patient population, while the predicted mPFS of placebo group was 7 months according to the results of STUPP and AVAGlio trials. The median OS was 18.69 months (95% CI, 15.90-26.71). The 1-year overall survival rate is 75.71% (95% CI, 64.82%-79.11%), and the 2-year overall survival rate is 42.04% (95% CI, 33.14%-50.67%). 26.8% of patients experienced at least one grade 3 or higher treatment-related adverse events (TRAEs). 11.1% of patients experienced serious treatment-related adverse events. The most frequent grade 3 or higher TRAEs were lymphocytopenia, thrombocytopenia, leukopenia, decreased neutrophil count. CONCLUSION The current research findings, conducted under the condition of data blinding, suggest that the combination of anlotinib with the STUPP regimen demonstrates promising therapeutic efficacy and favorable tolerability in the treatment of patients. These results indicate the potential of this treatment modality as a viable option in clinical practice.